Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903083 | 0.80 | ALDH1A1 (0.47) | SLC6A4SLC6A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL4909567 | 0.80 | CYP3A4 (0.41) | CYP3A4CYP2C19CYP2C9CCR2CCR4 | |
| SCHEMBL4910281 | 0.79 | CCR2 (0.53) | CYP3A4CYP2C19CYP2C9CCR2CCR4 | |
| SCHEMBL4907503 | 0.76 | RAB9A (0.40) | — | |
| SCHEMBL4911233 | 0.74 | ALOX5AP (0.38) | CYP3A4CYP2C19CYP2C9CCR2CCR4 | |
| SCHEMBL14006333 | 0.74 | CYP1A2 (0.49) | SLC6A4SLC6A2SLC6A3CYP3A4CYP2C19 | |
| SCHEMBL4911596 | 0.73 | CCR2 (0.74) | CYP3A4CYP2C19CYP2C9CCR2CCR4 | |
| SCHEMBL4902844 | 0.72 | L3MBTL1 (0.43) | CYP3A4CYP2C19CYP2C9CCR2CCR4 | |
| SCHEMBL305726 | 0.72 | MEN1 (0.48) | CYP3A4CYP2C19CYP2C9CCR2CYP1A2 | |
| SCHEMBL27944732 | 0.70 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| WO-2007067875-A2 | PYRIDINYL SULFONAMIDE MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMTED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | CCR2, CCR1, CCRL2 | SLC6A4 1653/4885SLC6A2 1992/4885SLC6A3 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.